Interferon-α-Induced Depression: When a Randomized Trial Is Not a Randomized Controlled Trial

  title={Interferon-$\alpha$-Induced Depression: When a Randomized Trial Is Not a Randomized Controlled Trial},
  author={G. Ranjith},
  journal={Psychotherapy and Psychosomatics},
  pages={387 - 387}
  • G. Ranjith
  • Published 2005
  • Psychology
  • Psychotherapy and Psychosomatics
Patten and Barbui [1] have performed a singular service to the profession by carrying out a systematic review on drug-induced depression. Their recommendations are based on studies that have randomly allocated patients into study and control groups, and the authors have provided an adequate justifi cation for this being the most scientifi c approach. This letter is to point out that the authors have erroneously designated a study as a randomized controlled trial. The authors state that… Expand
Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy
The present study provides the first evidence of an association between CHC and MDD, diagnosed on the basis of well-defined international criteria, independent of treatment with IFN-alpha and is not influenced by substance or alcohol abuse. Expand
Various types of randomized controlled trials, their characteristics, the process of randomization, and advantages and drawbacks of randomizedcontrolled trials are reviewed with special emphasis on the latter. Expand
Implementing Randomization: An Overview in the Field of Clinical Trials
Clinical trials are based on Human subjects, from phase I to phase IV, there are more number of human subjects involved to find or improve the medicine to serve the human society. Hence it is veryExpand
Chronic Hepatitis C is associated with high percentage of anxiety and depression in the affected individuals and adds to the morbidity of the disease. Expand
Evaluating the effects of Moringa oleifera on atherogenic lipoprotein indices of HIV infected Nigerian adults on tenofovir-based antiretroviral regimen
Along with the changes in fat disorder, other metabolic abnormalities identified in patients on combination ART included the disorder of lipoprotein metabolism, diabetes, irresponsiveness to insulin, and steatohepatitis. Expand
Randomization and Randomized Control Trial
Randomized control trial (RCT) is most simplest and powerful tools in clinical research. In this, participants are assigned by chance to different groups of interventions for comparison. By assigningExpand
Current awareness: Pharmacoepidemiology and drug safety
  • Medicine
  • Pharmacoepidemiology and drug safety
  • 2008
The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety in order to keep subscribers up‐to‐date with the latest developments in their field. Expand
Hepatitis C virus infection is independently associated with depression among methadone maintenance treatment heroin users in China
Depression and hepatitis C virus (HCV) infection are two common conditions among heroin users in methadone maintenance treatment (MMT). However, the comorbid relationship between depression and HCVExpand
Early Numeracy Intervention for Low-Performing Kindergartners
Early numeracy in kindergarten has proven to be a strong predictor of mathematical achievement. The aims of this study were to test the effectiveness of a remedial numeracy program for children whoExpand
Examining the Impact of Ranking on Consumer Behavior and Search Engine Revenue
The study unravels the economic impact of ranking and its interaction with social media on product search engines and suggests that providing more information during the decision-making process may lead to fewer consumer purchases because of information overload. Expand


Interferon Alpha-Induced Depression in Chronic Hepatitis C Patients: Comparison between Different Types of Interferon Alpha
A very careful selection of hepatitis C patients is required before starting IFN alpha therapy, as leukocyte IFNAlpha seemed to present a more elevated tolerability than other IFNalpha types available for clinical practice. Expand
The phenomenology and treatment of interferon-induced depression.
Review of the literature suggests that symptoms of depression induced by IFN therapy, in particular IFN-alpha therapy, are common and can limit the treatment utility, often necessitating discontinuation ofIFN therapy or the use of psychopharmacologic agents. Expand
Drug-Induced Depression: A Systematic Review to Inform Clinical Practice
Evidence was found linking corticosteroids, interferon-α, interleukin-2, gonadotropin-releasing hormone agonists, mefloquine, progestin- releasing implanted contraceptives and propranolol to the etiology of atypical depressive syndromes. Expand
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.
Development of moderate to severe depressive symptoms occurred frequently during PEG IFN/ribavirin treatment and was predicted by baseline depression scores and higher doses of ribavirin, but only through association with elevated baseline depression status. Expand
Neuropsychiatric Adverse Effects of Interferon-α
Recombinant preparations of the cytokine interferon (IFN)-α are increasingly used to treat a number of medical conditions, including chronic viral hepatitis and several malignancies. AlthoughExpand
Neuropsychiatric adverse effects of interferon-alpha: recognition and management.
Depression-specific symptoms are highly responsive to serotonergic antidepressants, whereas neurovegetative symptoms are significantly less responsive to these agents, and these symptoms may be more effectively treated by agents that modulate catecholaminergic functioning. Expand
Early increase in vegetative symptoms predicts IFN-α-induced cognitive-depressive changes
During IFN-α treatment, vegetative symptoms of depression appear earlier than, and are predictive of, their cognitive counterparts, which suggests that low mood state may in part be driven by the increase in early vegetative-depressive symptoms in the course of IFn-α-induced immune activation. Expand
+1 403 220 8752, Fax +1 403 270 7307 , E-Mail patten@ucalgary
    MRCPsych Bethlem Royal Hospital
      Patten Department of Community Health Sciences University of Calgary, 3330 Hospital Drive NW Calgary